Prosonix to Present at RDD 2012 and ATS 2012 International Conference
Complete the form below to unlock access to ALL audio articles.
Prosonix will be presenting its novel approach to developing respiratory medicines based on its particle engineering technology at two major international conferences during May.
Senior Management from the Company will attend Respiratory Drug Delivery (RDD 2012) in Phoenix, AZ, USA (May 13-17) and then the American Thoracic Society International Conference (ATS 2012) in San Francisco, CA, USA (May 18-23).
At RDD 2012, Prosonix will present a poster entitled ‘Engineered Combination Respiratory Medicines for Localized Drug Delivery,’ which will describe the development and in vitro performance of excipient-free, drug-only Multi-component Particles™ (MCPs™) for pressurized metered dose inhalers (pMDI).
The authors describe the engineering of MCPs™ consisting of budesonide (BDS) and formoterol fumarate dehydrate (FFD) in exact and consistent ratios, and demonstrate uniform and repeatable delivery of co-associated BDS-FFD particles using a lung impactor model (Anderson Cascade Impactor).
The poster will be available in the publications section on www.prosonix.co.uk from 11:30am MST/7:30pm BST on 14 May 2012.
Prosonix is currently evaluating MCPs™ incorporating inhaled corticosteroids (ICS) plus long-acting beta-agonists (LABAs), LABAs with long-acting muscarinic antagonists (LAMAs), and triple ICS/LABA/LAMA combinations.
Such MCPs™ offer the potential to achieve a true synergistic clinical effect between the active pharmaceutical ingredients at the target site in the lung, optimal therapeutic efficacy and reduced dosing.
Prosonix is also a Silver Sponsor of RDD 2012 and is sponsoring a session on Thursday 17 May (08:30-12:00) entitled ‘To (b) or (j) - That is the Question!’ examining the different regulatory routes for respiratory medicines in the US covering directly substitutable ‘generic’ generics (505j) and new formulations or branded generics (505b2).
In addition, the Company will showcase its unique respiratory drug development capabilities and the progress it is making with novel excipient-free, drug-only mono- and combination therapies in its pipeline at Booth 60 at RDD 2012, and Booth 734 at ATS 2012.